Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-Related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Publication date: Nov 26, 2024

The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.

Concepts Keywords
Arthritis Arthritis
Pediatric Bimekizumab
Pharmacokinetics
Recruiting
Years

Semantics

Type Source Name
drug DRUGBANK Bimekizumab
disease MESH Juvenile Idiopathic Arthritis
disease MESH Arthritis
disease MESH Ankylosing Spondylitis

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *